Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages 427-432

  Del Tordello, Elena ^a,c   Vacca, Irene ^a   Ram, Sanjay ^b   Rappuoli, Rino ^a   Serruto, Davide ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Immune evasion; Serum resistance

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT COMPONENT C3; NALP PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BLOOD; COMPLEMENT SYSTEM; CONTROLLED STUDY; DELETION MUTANT; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION;

IMMUNE EVASION; SERUM RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COMPLEMENT C3; COMPLEMENT C3B; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; DNA; ESCHERICHIA COLI; GENE DELETION; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; PHENOTYPE; PROTEIN BINDING; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID; SERINE ENDOPEPTIDASES; SERUM; SPECIES SPECIFICITY; SUBCELLULAR FRACTIONS; TIME FACTORS;

EID: 84891910226     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321556111     Document Type: Article

References (43)

1. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369(9580): 2196-2210.
2. Virji M (2009) Pathogenic neisseriae: Surface modulation, pathogenesis and infection control. Nat Rev Microbiol 7(4): 274-286.
3. Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4(3): 359-395.
4. Ram S, Lewis LA, Rice PA (2010) Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23(4): 740-780.
5. Jongerius I, Ram S, Rooijakkers S (2009) Bacterial complement escape. Adv Exp Med Biol 666: 32-48.
6. Rambach G, Würzner R, Speth C (2008) Complement: An efficient sword of innate immunity. Contrib Microbiol 15: 78-100.
7. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JA (2010) Molecular mechanisms of complement evasion: Learning from staphylococci and meningococci. Nat Rev Microbiol 8(6): 393-399.
8. Rooijakkers SH, van Strijp JA (2007) Bacterial complement evasion. Mol Immunol 44(1-3): 23-32.
9. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6(2): 132-142.
10. Madico G, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177(1): 501-510.
11. Seib KL, et al. (2009) Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77(1): 292-299.
12. Lewis LA, Carter M, Ram S (2012) The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol 188(10): 5063-5072.
13. Lewis LA, et al. (2010) The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6(7):e1001027.
14. Echenique-Rivera H, et al. (2011) Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog 7(5):e1002027.
15. Turner DP, Wooldridge KG, Ala'Aldeen DA (2002) Autotransported serine protease A of Neisseria meningitidis: An immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun 70(8): 4447-4461.
16. van Ulsen P, et al. (2003) A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol 50(3): 1017-1030.
17. Saunders NJ, et al. (2000) Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol Microbiol 37(1): 207-215.
18. Roussel-Jazédé V, Grijpstra J, van Dam V, Tommassen J, van Ulsen P (2013) Lipidation of the autotransporter NalP of Neisseria meningitidis is required for its function in the release of cell-surface-exposed proteins. Microbiology 159(Pt 2): 286-295.
19. van Ulsen P, et al. (2006) A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis. Microbes Infect 8(8): 2088-2097.
20. Serruto D, et al. (2010) Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 107(8): 3770-3775.
21. Roussel-Jazédé V, Jongerius I, Bos MP, Tommassen J, van Ulsen P (2010) NalPmediated proteolytic release of lactoferrin-binding protein B from the meningococcal cell surface. Infect Immun 78(7): 3083-3089.
22. Arenas J, Nijland R, Rodriguez FJ, Bosma TN, Tommassen J (2013) Involvement of three meningococcal surface-exposed proteins, the heparin-binding protein NhbA, the α-peptide of IgA protease and the autotransporter protease NalP, in initiation of biofilm formation. Mol Microbiol 87(2): 254-268.
23. Boulton IC, et al. (1999) Purified meningococcal transferrin-binding protein B interacts with a secondary, strain-specific, binding site in the N-terminal lobe of human transferrin. Biochem J 339(Pt 1): 143-149.
24. Granoff DM, Welsch JA, Ram S (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77(2): 764-769.
25. Terao Y, et al. (2008) Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem 283(10): 6253-6260.
26. Wexler DE, Chenoweth DE, Cleary PP (1985) Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 82(23): 8144-8148.
27. Park SY, et al. (2008) Immune evasion of Enterococcus faecalis by an extracellular gelatinase that cleaves C3 and iC3b. J Immunol 181(9): 6328-6336.
28. Laarman AJ, et al. (2011) Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J Immunol 186(11): 6445-6453.
29. Orth D, et al. (2010) EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5. Infect Immun 78(10): 4294-4301.
30. Ramu P, et al. (2007) The surface protease PgtE of Salmonella enterica affects complement activity by proteolytically cleaving C3b, C4b and C5. FEBS Lett 581(9): 1716-1720.
31. Gray-Owen SD, Schryvers AB (1993) The interaction of primate transferrins with receptors on bacteria pathogenic to humans. Microb Pathog 14(5): 389-398.
32. Sadarangani M, Pollard AJ, Gray-Owen SD (2011) Opa proteins and CEACAMs: Pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 35(3): 498-514.
33. Sim RB, Twose TM, Paterson DS, Sim E (1981) The covalent-binding reaction of complement component C3. Biochem J 193(1): 115-127.
34. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE (1995) C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181(6): 2119-2127.
35. Elsner J, et al. (1994) C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24(3): 518-522.
36. Elsner J, Oppermann M, Czech W, Kapp A (1994) C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83(11): 3324-3331.
37. Klos A, et al. (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46(14): 2753-2766.
38. Bokisch VA, Müller-Eberhard HJ (1970) Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest 49(12): 2427-2436.
39. Matthews KW, et al. (2004) Expression of the third complement component (C3) and carboxypeptidase N small subunit (CPN1) during mouse embryonic development. Dev Comp Immunol 28(6): 647-655.
40. Sayah S, et al. (2003) Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res Mol Brain Res 112(1-2): 53-60.
41. Oldfield NJ, et al. (2013) Prevalence and phase variable expression status of two autotransporters, NalP and MspA, in carriage and disease isolates of Neisseria meningitidis. PLoS One 8(7):e69746.
42. Jain S, et al. (2006) Polar localization of the autotransporter family of large bacterial virulence proteins. J Bacteriol 188(13): 4841-4850.
43. Lo H, Tang CM, Exley RM (2009) Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 9(7): 418-427.